同种异体造血细胞移植治疗Still病:2024年NextGen会议多学科视角
本文总结2024年系统性JIA基金会NextGen会议关于同种异体造血细胞移植(HCT)治疗难治性Still病(SD)的专家观点。反复MAS、进行性肺病、IL-1/IL-6/JAK抑制剂治疗下持续全身炎症及糖皮质激素依赖可考虑HCT;现有数据多来自小规模儿科队列,显示部分患者可实现临床缓解和肺部改善,但移植相关死亡率仍高,尤其合并肺病者,且炎症病可能复发;成人数据有限。
要点
- 反复MAS、进行性肺病、IL-1/IL-6/JAK抑制下持续炎症及激素依赖可考虑异体HCT。
- 现有数据主要来自小规模儿科队列,部分患者可实现临床缓解和肺部改善。
- 移植相关死亡率仍高,尤其合并肺病者,且HCT后炎症病可能复发。
核心结论
- 对选择性严重难治性Still病患者,尤其反复MAS和/或进行性肺病者,可考虑同种异体HCT。
- 早期多学科评估、共同决策和仔细患者选择至关重要。
研究设计与样本
- 本文为会议总结,基于2024年系统性JIA基金会NextGen会议的报告和多学科讨论。
- 会议召集了风湿病学家、移植医师、免疫学家、肺病学家和患者倡导者的国际多学科小组。
主要发现
- 反复MAS、进行性肺病、IL-1/IL-6/JAK抑制下持续全身炎症和糖皮质激素依赖被确定为可能需考虑异体HCT的临床特征。
- 现有数据主要来自小规模儿科队列,提示异体HCT可在部分患者中实现临床缓解和改善肺部结局。
- 移植相关死亡率仍高,尤其合并肺病者,且HCT后炎症病可能复发。
- 成人HCT数据仍有限。
临床怎么用
- 对严重难治性Still病,尤其反复MAS和/或进行性肺病者,可考虑异体HCT。
- 需早期多学科评估、共同决策和仔细患者选择。
- 需开展前瞻性多中心研究并加强儿科与成人医师合作以优化患者选择和改善结局。
局限性
- 现有数据主要来自小规模儿科队列,成人数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) represent a spectrum of Still's disease (SD) characterized by dysregulated innate immunity, severe systemic inflammation, and risk of life-threatening complications including macrophage activation syndrome (MAS) and associated lung disease (LD). Although IL-1 and IL-6 pathway inhibitors have improved outcomes, a subset of patients develop severe, refractory disease. This article summarizes the current evidence and multidisciplinary expert perspectives on the role of allogeneic hematopoietic cell transplantation (HCT) in refractory Still's disease. METHODS: This Special Article is a conference summary based on presentations and multidisciplinary discussion at the 2024 Systemic JIA Foundation NextGen Conference, which convened an international, multidisciplinary group of rheumatologists, transplant physicians, immunologists, pulmonologists, and patient advocates. RESULTS: Recurrent MAS, progressive LD, persistent systemic inflammation despite IL-1/IL-6/JAK inhibition, and glucocorticoid dependence were identified as clinical features that may warrant consideration of allogeneic HCT in SD. Available data, mainly from small pediatric cohorts, suggest that allogeneic HCT can achieve clinical remission and improve pulmonary outcomes in select patients. However, transplant-related mortality remains substantial, particularly in patients with LD, and inflammatory disease may recur after HCT. HCT data in adults remain limited. CONCLUSION: Allogeneic HCT may be considered for select patients with severe, refractory SD, particularly those with recurrent MAS and/or progressive LD. Early multidisciplinary evaluation, shared decision-making, and careful patient selection are essential. Prospective multicenter studies and closer collaboration between pediatric and adult providers are needed to refine patient selection and improve outcomes.
引用
- Chandra S, Marsh RA, Silva JMF, et al. Current State of Allogeneic Hematopoietic Cell Transplantation for Still's Disease: A Collaborative Perspective from Attendees of the Systemic Juvenile Idiopathic Arthritis Foundation NextGen Conference. Arthritis Care Res (Hoboken). 2026. PMID: 42901710. doi:10.1002/acr.80191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。